Surgical Science Sweden AB (publ) (SUS.ST)
SEK 108.6
(-6.54%)
SEK 108.6
(-6.54%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 246.9 Million SEK | -5.43% |
| 2022 | 271.29 Million SEK | 113.52% |
| 2021 | 115.04 Million SEK | 230.9% |
| 2020 | 30.22 Million SEK | 21.69% |
| 2019 | 30.36 Million SEK | 401.16% |
| 2018 | -1.95 Million SEK | -12.34% |
| 2017 | -2.25 Million SEK | -18.68% |
| 2016 | 8.58 Million SEK | -4.49% |
| 2015 | 8.9 Million SEK | 336.65% |
| 2014 | 2.03 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 36.95 Million SEK | -80.41% |
| 2024 Q2 | 45.78 Million SEK | 28.7% |
| 2023 Q3 | 50.69 Million SEK | 6.64% |
| 2023 FY | - SEK | -5.43% |
| 2023 Q1 | 53.26 Million SEK | -50.75% |
| 2023 Q2 | 47.53 Million SEK | -10.76% |
| 2023 Q4 | 68.05 Million SEK | 34.26% |
| 2022 Q1 | 20.01 Million SEK | -73.9% |
| 2022 FY | - SEK | 113.52% |
| 2022 Q4 | 108.15 Million SEK | 153.25% |
| 2022 Q3 | 42.7 Million SEK | 10.67% |
| 2022 Q2 | 38.59 Million SEK | 92.79% |
| 2021 Q2 | 2.23 Million SEK | -0.58% |
| 2021 Q1 | 2.24 Million SEK | -82.26% |
| 2021 FY | - SEK | 230.9% |
| 2021 Q4 | 76.7 Million SEK | 913.17% |
| 2021 Q3 | 7.57 Million SEK | 239.51% |
| 2020 Q1 | -807 Thousand SEK | -106.5% |
| 2020 Q3 | 7.3 Million SEK | 772.28% |
| 2020 Q4 | 12.64 Million SEK | 73.17% |
| 2020 FY | - SEK | 21.69% |
| 2020 Q2 | 837 Thousand SEK | 203.72% |
| 2019 Q1 | -5.06 Million SEK | -191.17% |
| 2019 FY | - SEK | 401.16% |
| 2019 Q3 | 9.5 Million SEK | 666.89% |
| 2019 Q4 | 12.42 Million SEK | 30.72% |
| 2019 Q2 | -1.67 Million SEK | 66.93% |
| 2018 Q2 | 800 Thousand SEK | 142.11% |
| 2018 FY | - SEK | -12.34% |
| 2018 Q3 | 1.6 Million SEK | 100.0% |
| 2018 Q4 | 5.55 Million SEK | 247.44% |
| 2018 Q1 | -1.9 Million SEK | -135.11% |
| 2017 Q4 | 5.41 Million SEK | 1182.4% |
| 2017 Q1 | 2 Million SEK | -80.39% |
| 2017 FY | - SEK | -18.68% |
| 2017 Q2 | 100 Thousand SEK | -95.0% |
| 2017 Q3 | -500 Thousand SEK | -600.0% |
| 2016 Q2 | -200 Thousand SEK | -125.0% |
| 2016 Q1 | 800 Thousand SEK | 0.0% |
| 2016 Q3 | -2.2 Million SEK | -1000.0% |
| 2016 FY | - SEK | -4.49% |
| 2016 Q4 | 10.2 Million SEK | 563.64% |
| 2015 FY | - SEK | 336.65% |
| 2014 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Aino Health AB (publ) | -7.52 Million SEK | 3379.32% |
| Bonzun AB (publ) | -28.58 Million SEK | 963.747% |
| Kontigo Care AB (publ) | 1.67 Million SEK | -14613.945% |
| Medhelp Care Aktiebolag (publ) | 10 Million SEK | -2368.506% |
| RaySearch Laboratories AB (publ) | 405.93 Million SEK | 39.178% |